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Abstract
Many cancer patients use integrative therapies with a combination of natural products and diets. 
In the Western world, integrative medicine is often not shared with oncologists even during 
antineoplastic treatments. This behavior stems from the unmet needs of cancer patients who 
may feel oncologists’ underestimation of their symptoms and spiritual aspects. This case report 
demonstrates the potential harm of inadequate diet and nutraceutical intake in a 68-year-old 
woman with metastatic estrogen receptor-positive, human epidermal growth factor receptor-
2-negative breast cancer. Her care team recommended hormone therapy with abemaciclib plus 
fulvestrant. Her diarrhea started after 10 days of therapy and did not disappear, despite the use 
of loperamide, causing a significant reduction in adherence and dose intensity of abemaciclib. 
The patient finally disclosed to her oncologist she was following a detoxifying diet and taking 
several nutraceuticals. Her diarrhea was correlated with abemaciclib but most probably exacer-
bated and prolonged by the diet. Evaluation of disease after 3 months showed progressive dis-
ease. Integrative medicine should be in the multidisciplinary management of cancer patients to 
avoid potentially harmful events and ameliorate patients’ quality of life in a holistic approach.
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Introduction
Metastatic breast cancer still represents a major cause of death in women [1]. To date, 
patients with estrogen receptor-positive, human epidermal growth factor receptor-2-neg-
ative (her-2) breast carcinoma are best managed with a combination of antihormonal agents 
and cyclin-dependent kinase 4 and 6 inhibitors. Among the latter class, abemaciclib is the 
most potent in preclinical studies [2]. Such combination therapy may achieve a median 
disease-free survival of 46 months with good tolerability in breast cancer patients progressing 
during endocrine therapy [3].
Recently, the role of integrative medicine has gained popularity in a more open, multidis-
ciplinary, holistic way of interpreting oncology and unmet patients’ needs [4–6]. Many 
patients follow detoxifying or anticancer diets and take nutraceuticals often without discussion 
with their treating oncologists [7]. This attitude toward the use of nutraceuticals should be 
carefully evaluated in a team of integrative medicine since natural products does not always 
correspond to safety in oncology [8]. This article reports a negative interaction between 
detoxifying diet and nutraceuticals with adherence to antihormonal therapy in a woman with 
advanced estrogen receptor-positive, her-2-negative breast cancer.
Case Report
Written informed consent was obtained from the patient for publication of this case 
report and any accompanying images. A 68-year-old woman – a housewife – presented with 
suspect progressive breast cancer while taking adjuvant letrozole for 3 years. In February 
2018, she was diagnosed with breast cancer and received conservative left breast surgery 
with axillary dissection after sentinel lymph node analysis was positive for cancer. The 
systemic staging was negative for metastatic disease. Pathology showed a ductal infiltrating 
carcinoma estrogen receptor 80%, progestin receptor 35%, her-2 score 1, and Ki67 40%. The 
clinical and pathological stage was pT2, N1, M0. She received an adjuvant chemotherapy 
regimen with epirubicin and cyclophosphamide every 3 weeks for 4 cycles, followed by pacli-
taxel for 12 weeks, complementary radiotherapy on the left breast and the homolateral axilla, 
and started adjuvant letrozole. In May 2020, she was admitted to our outpatients’ clinic 
because of a Ca15.3 increase. A positron emission tomography/CT (PET/CT) showed 
progressive disease at nodes, bone, and an unspecific liver uptake. Physical examination was 
nonsignificant, and the patient denied any symptoms of the disease but moderate fatigue. She 
was classified as an estrogen receptor-positive, her-2/neu-negative, hormone-resistant 
breast carcinoma.
The oncologist quitted letrozole. Based on scientific data, the oncologist proposed a 
systemic treatment with fulvestrant 500 mg every 2 weeks as a loading dose 3 times and then 
every 4 weeks, plus abemaciclib 150 mg bid on a continuous schedule [3]. The patient’s 
performance status was adequate for abemaciclib plus fulvestrant regimen with an Eastern 
Cooperative Oncology Group Performance Status score of 1. The oncologist carefully inter-
viewed the patient for concomitant gastrointestinal diseases that could contraindicate 
abemaciclib use and other drug assumptions. The oncologist performed a drug-drug inter-
action evaluation employing a drug checker tool and explained in detail abemaciclib to the 
patient and her daughter, including written precise suggestions concerning potential side 
effects. More specifically, the oncologist stressed the precocious use of loperamide and dietary 
modification in case of diarrhea. He recommended immediately taking loperamide at first or 
second liquid stool and contacting the medical oncology team via a WhatsApp messenger 
system (Fig. 1).
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After 10 days, she complained of grade 2 diarrhea, according to the National Cancer 
Institute Common Toxicity Criteria version 5.0 [9]. Nurses called the patient to assure she was 
following a correct astringent diet and loperamide assumption. A blood test showed only a 
mild increase in serum creatinine. Since she reported intermittent diarrhea, the oncologist 
Fig. 1. Treatment timeline.
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reduced the abemaciclib dose to 100 mg bid, but intestinal movements remained unchanged 
and stopped abemaciclib for 3 days. Such drug-free periods occurred every 2 weeks, with no 
other significant side effects.
At this point, the patient disclosed she was following a detoxifying diet prescribed by a 
dietician. Oncologists were not aware of it. The dietician did not make any effort to contact 
the managing oncologists. Table 1 depicts the diet components. As shown in Table 2, she was 
also taking several integrative agents such as broccoli extracts (250 mg bid), garlic extracts 
(500 mg bid), high-dose vitamin D, curcumin plus black pepper (526 mg bid), green tea (3 
serving/day), vitamin C (500 mg/day), lipoic acid 100 mg/day, coenzyme q10 100 mg/day, 
vitamin K (250 mcg/day), selenium (75 mcg/day), and iodine (150 mcg/day). The dietary 
prescription also reported that “people may experience weakness, stool modification 
including diarrhea, and generalized pain, which are positive signs of detoxification.” Accord-
ingly, the patient showed evident difficulties in decoding her gastrointestinal symptoms. The 
oncologist stopped the diet, and diarrhea frequency reduced in 2 weeks. The dose intensity 
of abemaciclib was 68.5% of the planned one, according to the Hyrnuk and Bush formula [10]. 
After 3 months of abemaciclib and fulvestrant, a new PET/CT showed progressive disease 
according to the RECIST criteria. Besides reversible diarrhea G3 and renal toxicity (creat-
inine) G1, no other significant adverse events were observed according to the NCCN-CTC 
criteria [9]. The oncologist’s decision was to withheld fulvestrant and abemaciclib and 
proposed a second-line treatment of everolimus and exemestane. She is still alive during the 
time of writing.
Discussion
Abemaciclib may be administered with or without food, and food-drug interaction 
analysis showed that diet has modest effects on the pharmacokinetics of abemaciclib [11]. A 
high-fat, high-calorie meal administered to healthy subjects increased the C-max and AUC of 
abemaciclib plus its active metabolites by 26% and 9%, respectively. Grapefruit juice may 
increase the plasma concentrations of abemaciclib and therefore should be avoided. The 
possible mechanism is the inhibition of CYP450 3A4-mediated first-pass metabolism in the 
gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may 
also contribute. According to product labeling, abemaciclib systemic exposure (AUC) is 
predicted to increase up to 16-fold when administered with the potent CYP450 3A4 inhibitor 
ketoconazole.
In this study, we report the inappropriate use of a detoxifying diet with a massive daily 
administration of herbal and nutraceutical agents in a female patient treated with fulvestrant 
plus abemaciclib for metastatic breast cancer. This patient showed poor response to antihor-
monal therapy, as shown by PET/CT, and reported chronic diarrhea, which hampered 
treatment adherence and drug dose intensity by one-third of the planned dose. Neither the 
patient nor the family caregiver or the dietician informed the oncology center. Suspension of 
the diet by the treating oncologist resulted in the weakening of diarrhea. Although usual diet 
habits seem not to influence abemaciclib pharmacokinetics, an incorrect diet may cause 
gastrointestinal disturbances. These may favor the occurrence of abemaciclib-related 
diarrhea, causing dose reductions and poor adherence and eventually negatively influencing 
patients’ outcomes and quality of life.
Our patient was taking many compounds with possible negative interaction on treatment 
outcome. Supplementation with coenzyme q10 and vitamins caused a more unsatisfactory 
outcome in patients with metastatic breast cancer treated with chemotherapy in a Southwest 
Oncology Group trial [12]. Although the herb-drug interaction risk for short-term use of garlic 
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is low, prolonged exposure to concentrated garlic extracts may counteract the efficacy of 
drugs whose disposition depends on the human efflux transporter ABCB1 which may occur 
in tumor cells [13, 14]. Even if the check for interactions between the single nutraceuticals 
and antihormonal agents employed in our patient was negative, knowledge on the possible 
effects of the whole “orchestra” of agents is poor.
In clinical practice, oncologists commonly check drug-drug interactions when prescribing 
modern targeted therapies. On the other hand, herb-drug or food/diet-drug is far less 
explored, even if herb-drug interaction checkers are available [15]. In this patient, while such 
a check did not show negative interaction between antihormonal agents and supplements, 
the diet followed caused a sharpening and prolongation of liquid stools, causing poor 
adherence and dose reduction of abemaciclib. Moreover, the reckless pieces of information 
about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient. 
Today, herbal supplements and nutraceuticals in various forms can be easily purchased over 
the counter and widely employed by cancer patients, often without discussing with their 
oncologists. This hidden behavior is probably related to sometimes justified patients’ 
perception that their needs in terms of quality of life are underweighted by most oncologists 
far more concentrated on therapy management [16]. Herbal supplements and nutraceuticals 
are often self-prescribed or suggested by friends, other patients, or prescribed by profes-
sionals other than oncologists. Such prescriptions are often not shared, even if patients should 
discuss its use with the managing oncologist and pharmacist. The regulatory agencies do not 
pay the same attention for pharmaceutical drugs to herbals, dietary supplements, and their 
manufacturers.
Conclusion
Although integrative medicine has a significant positive role in managing people 
affected by cancer, a careful approach is advisable since herbal supplements and nutra-
ceuticals may enhance prescription medications’ side effects and block the intended ther-
apeutic drug efficacy. It is then advisable that deep and correct information be delivered 
to patients about the potential benefits but especially about the possible interactions of 
herbal supplements and nutraceuticals that may occur with the standard therapies 
administered. For this purpose, a multidisciplinary approach is essential to treat this kind 
of patients.
Table 2. Nutraceuticals Agent Dosage
Broccoli extracts 250 mg bid
Garlic extracts 500 mg bid
Curcumin 526 mg bid
Coenzyme q10 100 mg/once a day
Vitamin K 250 mcg/once a day
Vitamin C 500 mg/once a day
Lipoic acid 100 mg/once a day
Selenium 75 mcg/once a day
Iodine 150 mcg/once a day
Green tea Three serving/day
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